The European Union agreed to purchase about 300 million doses of the Coronavirus vaccine, which was announced by “Pfizer” and “Biontech”, after it showed effective results during experiments.
The companies said that deliveries are expected to begin by the end of this year. However, the European Union refused to disclose the details of how the vaccine was launched, and insisted that “a number of steps” be taken in advance.
Early data indicates that the vaccine protects more than 90 percent of people from developing symptoms of Covid-19.
The two companies said on Monday that the vaccine had tested 43,500 people without raising safety concerns.
Pfizer-Biontech plans to apply for emergency approval to use the vaccine by the end of November, and a limited number of people may benefit from it this year.
Stella Kyriakides, the European Union’s health commissioner, described the European vaccine deal as “very important”.
She said: “The agreement means that we are approaching a step from what we have started, to have a wide-ranging and effective vaccine portfolio,” adding that it will not be distributed until after “it is proven that it is safe.”
However, Kyriakides refused to provide details of a specific timetable for when the vaccine will be delivered to the member states of the European Union, and said: “You must obtain a license from the European Medicines Agency, there are steps that must be followed before we can actually set a schedule.”
She also warned, saying: “(The vaccine) will not be the magic solution that makes the virus disappear overnight.”
The post European Union buys 300 million doses of the “Pfizer-Biontech” vaccine appeared first on Flags News.